Terminated PHASE2 INTERVENTIONAL 1-arm NCT00837759

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Autoimmune Diabetes Diabetes Mellitus Type 1

Interventions Diamyd GAD65 (Diamyd) Insulin Lansoprazole Sitagliptin

Updated 6 times since 2017 Last updated: Dec 31, 2012 Started: Feb 28, 2009 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Changes to study personnel.

Other terminated trials from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

See all terminations from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

This PHASE2 trial investigates Autoimmune Diabetes and Diabetes Mellitus Type 1 and is currently terminated or withdrawn. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States